Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have ...

Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

Argus downgraded Moderna (MRNA) to Hold from Buy without a price target The firm sees limited upside for the stock over the next 12 months as ...

Covid vaccines are estimated to have prevented more ... In the US, citizens can pick between vaccines manufactures by Moderna, Pfizer and Novavax. According to CDC data, in about one in ...

as the Massachusetts firm announced the first patient had been tested with its potential coronavirus vaccine. Moderna is focused on development of vaccines based around mRNA, which present ...

A third dose of COVID-19 vaccine is beneficial among older Medicare beneficiaries, regardless of prior medically attended COVID-19 diagnoses.

Researchers developing Australia’s first mRNA Covid vaccine say they may have solved the one of the biggest problems with ...

All new Pfizer and Moderna vaccines target the Omicron variant KP.2 strain of SARS-CoV-2, the virus that causes COVID. Spikevax, the COVID-19 vaccine manufactured by Moderna and FDA-approved for ...

The first time I got a Novavax Covid vaccine, it felt almost subversive. Over the previous few years, every mRNA-based booster I’d gotten — the ones made by Moderna and Pfizer — had felt ...

Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss “next steps” with ...

However, the vaccine and its manufacturers received criticism because it was less effective than the mRNA Covid vaccines ...